Urinary tract infections and antibiotic resistance;Harnwegsinfektionen und Antibiotikaresistenz

Urologe - Ausgabe A

Volumn 49, Issue 5, 2010, Pages 612-617

  Heisig, P ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

lactam; Antibiotic resistance; Fluoroquinolones; Fosfomycin; Sulfonamide trimethoprim

Indexed keywords

BETA LACTAM ANTIBIOTIC; FOSFOMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; DRUG TARGETING; ENTEROCOCCUS; ESCHERICHIA COLI; REVIEW; URINARY TRACT INFECTION;

ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CROSS INFECTION; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; FEMALE; HEALTH SURVEYS; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 77955615618     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-010-2259-y     Document Type: Review

References (18)

1. Bagshaw SM, Laupland KB (2006) Epidemiology of intensive care unit-acquired urinary tract infections. Curr Opin Infect Dis 19:67-71
2. Drekonia DM, Johnson JR (2008) Urinary tract infections. Prim. Care Clin Office Pract 35:345-367
3. Kahlmeter G (2003) An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS project. J Antimicrob Chemother 51:69-76
4. Zhanel GG, Hisanage TL, Laing NM et al (2006) Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 27:468-475
5. Enne VI, Livermore DM, Stephens P, Hall LMC (2001) Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet 357:1325-1328
6. Johnson L, Sabel A, Burman WJ et al (2008) Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. Am J Med 121:876-884
7. Mazel D (2006) Integrons: agents of bacterial evolution. Nat Rev Microbiol 4:608-620
8. Lescat M, Calteau A, Hoede C et al (2009) A module located at a chromosomal integration hot spot is responsible for the multidrug resistance of a reference strain from Escherichia coli clonal group A. Antimicrob Agents Chemother 53:2283-2288
9. Hooton TM (2003) Fluoroquinolones and resistance in the treatment of uncomplicated urinary infection. Int J Antimicrob Agents 22:65-72
10. Heisig P (2009) Type II topoisomerases - inhibitors, repair mechanisms and mutations. Mutagenesis 24:465-469
11. Heisig P (2001) Inhibitors of bacterial topoisomerases: mechanisms of action and resistance and clinical aspects. Planta Med 67:3-12
12. Übersicht bei Strahilevitz J, Jacoby GA, Hooper DC (2009) Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev 22:664-689
13. Giske CG, Sundsfjord AS, Kahlmeter G et al (2009) Redefining extended-spectrum ß-lactamases: balancing science and clinical need. J Antimicrob Chemother 63:1-4
14. Gniadkowski M (2008) Evolution of extended- spectrum ß-lactamases by mutation. Clin Microbiol Infect 14(Suppl 1):11-32
15. Ena J, Arjona F, Martinez-Peinando C et al (2006) Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Urology 68:1169-1174
16. Popovic M, Steinort D, Pillai S, Joukhadar C (2010) Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis; online publication ahead of print doi: 10.1007/sl0096-009-0833-2
17. Cunha BA (1989) Nitrofurantoin: an update. Obster Gynecol Survey 44:399-406
18. BrumfittW, Hamilton-Miller JMT (1998) Efficacy and safety profile of long-term nitrofurantoin in urinary infections: 18 years' experience. J Antimicrob Chemother 42:363-371